The generic industry in Canada has a significant research base. Our largest member company, Apotex, has been the largest spender on pharmaceutical research and development for many years now in Canada. Apotex does both new chemical research—it owns a company Cangene, an arm of its own company—as well as research and development of the generic products in Canada.
Our percentage spend on research and development to sales is actually significantly higher than the brand companies in Canada. This is interesting, simply because we have a lot of that centred in Canada. Our ratio of R and D to sales is over 12%, and we have hundreds of jobs in R and D. I can't give you a precise number, but it's in the hundreds.